Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005982 · ClinicalTrials.gov registry record · Phase 2
506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00005982: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00005982 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005982, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma
Interventions
- OTHER pharmacological study
- DRUG nelarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2000-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005982
The ClinicalTrials.gov registry entry for NCT00005982 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pharmacological study is the first listed.
NCT00005982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005982 about?
NCT00005982 is a clinical study titled "506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma". Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma
What is the current status of trial NCT00005982?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2000-04.
What interventions are being tested in trial NCT00005982?
The interventions under investigation include: pharmacological study (OTHER), nelarabine (DRUG).
Who is sponsoring clinical trial NCT00005982?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.